- Cardiometabolismo
■ Atualização da Diretriz Brasileira de Dislipidemias e Prevenção da Aterosclerose – 2017
Faludi, André Arpad et al.
Arq. Bras. Cardiol., Ago 2017, vol.109, no.2, suppl.1, p.1-7
http://www.scielo.br/scielo.php?script=sci_arttext&pid=S0066-782X2017001100001&lng=pt&nrm=iso
■ Management of statin intolerance in 2018: Still more question than answers?
Peter P. Toth, Angelo Maria Patti, Rosaria Vincenza Giglio, DraganaNikolic, GiuseppaCastellino, Manfredi Rizzo, MaciejBanach
Am J CardiovascDrugs. 2018; vol 18(3): 157–173
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5960491/
■ Assessing gaps in cholesterol treatment guidelines for primary prevention of cardiovascular disease based on available randomized clinical trial evidence: The Rotterdam Study
JelenaPavlović, Philip Greenland, Jaap W Deckers et al
Eur J PrevCardiol. 2018, vol 25(4): 420–431
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5818030/
■ Estratificação de Risco Cardiovascular e Elegibilidade para Estatina com Base na Diretriz Brasileira vs. Norte-Americana para Manejo do Colesterol
Cesena, Fernando HenpinYue et al
Arq. Bras. Cardiol., June 2017, vol.108, no.6, p.508-517
■ Fitosteróis no Tratamento da Hipercolesterolemia e Prevenção de Doenças Cardiovasculares
Cabral, Carlos Eduardo and Klein, Márcia Regina Simas Torre
Arq. Bras. Cardiol., Nov 2017, vol.109, no.5, p.475-482
■ ACC/AHA guidelines superior to ESC/EAS guidelines for primary prevention with statins in non-diabetic Europeans: the Conpenhagen General Population Study
M B Mortensen, B G Nordestgaard, S Afzal, E Falk
European Heart Journal 2017, vol 38 (8): 586-594
https://academic.oup.com/eurheartj/article/38/8/586/2661782
■ 2016 ESC/EAS Guidelines for the management of dyslipidaemias
A L Catapano, I Graham, G De Backer et al
European Heart Journal 2016, vol 37 (39): 2999-3058
https://academic.oup.com/eurheartj/article/37/39/2999/2414995
■ A review of clinical practice guidelines for the management of hypertriglyceridemia: a focus on high dose omega-3 fatty acids
D G Karalis
AdvTher 2017, vol 34 (2): 300-323
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5331085/
■ Low-density lipoprotein cause atherosclerotic cardiovascular disease. 1. Evidence from genetic, epidemiologic, and clinical studies
A consensus statement from the European Atherosclerosis society Consensus Panel
B A Ference, H N Ginsberg, I Graham et al
European Heart Journal 2017, vol 38: 2459-2472
https://academic.oup.com/eurheartj/article/38/32/2459/3745109
■ Overview of guidelines for the management of dyslipidemia: EU perspectives
Vicente Giner-Galvañ, María José Esteban-Giner, Vicente Pallarés-Carratalá
Vasc Health Risk Manag. 2016; 12: 357–369
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5019442/
■ Cardiovascular disease and risk management: review of the American Diabetes Association Stnadards of Medicial Care
J J Chamberlain, E L Johnson, S Leal et al
Annals of Internal Medicine may 2018
■ Implication of American College of Cardiology/American Heart Association (ACC/AHA) Cholesterol Guidelines on Statin Underutilization for Prevention of Cardiovascular Disease in Diabetes Mellitus Among Several US Networks of Community Health Centers
EhimareAkhabue, Sarah S. Rittner, Joseph E. Carroll et al
J Am Heart Assoc. 2017 Jul; 6(7): e005627.
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5586289/
■ Diretriz brasileira baseada em evidências sobre prevenção de doenças cardiovasculares em pacientes com diabetes: posicionamento da Sociedade Brasileira de Diabetes (SBD), da Sociedade Brasileira de Cardiologia (SBC) e da Sociedade Brasileira de Endocrinologia e Metabologia (SBEM).
Faludi, André Arpad et al.
Arq. Bras. Cardiol., Dez 2017, vol.109, no.6, suppl.1, p.1-31
http://www.scielo.br/scielo.php?script=sci_arttext&pid=S0066-782X2017001600001&lng=en&nrm=iso
■ Cardiovascular effects of new oral glucose-lowering agents: DPP-4 and SGLT-2 inhibitors
André J. Scheen
Circ Res. 2018, vol 11; 122(10): 1439–1459
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5959222/
■ Diabetes screening in patients with macrovascular coronary disease: Are the new European guidelines a step backwards?
A Ribeiro, S B Baptista, M Faustino et AL
Acta Med Port 2017, vol 30 (6): 434-442
https://www.actamedicaportuguesa.com/revista/index.php/amp/article/viewFile/7990/5216
■ Added sugars and cardiovascular disease risk in children
M B Vos, J L Kaar, J A Welsh et al
Circulation 2017, vol 135: e1017-e1034
http://circ.ahajournals.org/content/135/19/e1017
■ 2016 Canadian Cardiovascular Society Guidelines for the Management of Dyslipidemia for the Prevention of Cardiovascular Disease in the Adult
T J Anderson, J Grégoire, A R Barry et al
Canadian Journal of Cardiology 2016, vol 32 (11): 1263-1282
https://www.onlinecjc.ca/article/S0828-282X(16)30732-2/fulltext
■ Dietary fats and cardiovascular disease
A Presidential Advisory From the American Heart Association
F M Sacks, A H Lichtenstein, J H Y Wu et al
Circulation 2017: vol 136:e1-e23
http://circ.ahajournals.org/content/136/3/e1
■ Percent reduction in LDL cholesterol following high-intensity statin therapy: potential implications for guidelines and for the prescription of emerging lipid-lowering agents
P M Ridker, S Mora, L Rose – the JUPITER Trial Study Group
European Heart Journal 2016,vol 37 (1): 1373-1379
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4852064/
■ Guias ESC/EAS 2016 sobre el tratamiento de lãs dislipidemias
Grupo de Trabajo de la Sociedad Europea de Cardiologia (ESC) y la European Atherosclerosis Society (EAS) sobre el tratamiento de las dislipidemias
Rev Esp Cardiol 2017, vol 70 (2)
www.revespcardiol.org/es/pdf/90460573/S300
■ Guidelines for the treatment of cholesterol to reduce atherosclerotic cardiovascular risk: implications for US Hispanics/Latinos based on findings from the Hispanic Community Health Study/Study of Latinos (HCHS/SOL)
American College of Cardiology/American Heart Association (ACC/AHA)
Waqas T. Qureshi, Robert C. Kaplan, KatrinaSwett, Gregory Burke, Martha Daviglus, Molly Jung, Gregory A. Talavera, Diana A. Chirinos, Samantha A. Reina, Sonia Davis, Carlos J. Rodriguez
J Am Heart Assoc. 2017 May; 6(5): e005045
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5524073/
■ Omega-3 polyunsaturated fatty acid (fish oil) supplementation and the prevention of clinical cardiovascular disease
D S Siscovick, T A Barringer, A M Fretts et al
Circulation 2017, vol 135: e867-884
http://circ.ahajournals.org/content/135/15/e867
■ Meal timing and frequency: implications for cardiovascular disease prevention
A Scientific Statement From the American Heart Association
M St-Onge, J Ard, M L Baskin et al
Circulation 2017, vol 135: e96-e121
http://circ.ahajournals.org/content/135/9/e96
■ by Dr Paulo Fernando Leite
Cardiologia/Prevenção Cardiovascular
Centro Médico Unimed BH
Autor dos livros:
– Fisiologia, Ergometria & Condicionamento Físico – 2006
– Fatores Nutricionais e Metabólicos de Risco Cardiovascular – – 2002
– Coordenador Científico da MedWebServiços – www.mwsedumed.com.br